News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 196781

Wednesday, 11/19/2014 6:20:46 PM

Wednesday, November 19, 2014 6:20:46 PM

Post# of 347009
Hakan Mellstedt : Peregrine Pharmaceuticals KOL :


The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

Nov 19, 2014



Amir Hossein Daneshmanesh 1,

Mohammad Hojjat-Farsangi 1,

Ali Moshfegh 1,

Abdul Salam Khan 1,

Eva Mikaelsson 1,

Anders Österborg 1,2 and

Håkan Mellstedt 1,2

Author Information

1 Department of Oncology-Pathology, Immune and Gene Therapy Lab, CCK, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden

2 Departments of Oncology and Hematology, Karolinska University Hospital Solna, Stockholm, Sweden


Article first published online: 19 NOV 2014

DOI: 10.1111/bjh.13228

http://onlinelibrary.wiley.com/doi/10.1111/bjh.13228/full



------------------------------------------------------

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y